BridgeBio Pharma, Inc.: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Aug 11, 2020 and accepted by EDGAR at Aug 11, 2020, 17:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2020-04-01 to 2020-06-30 | $86.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2020-01-01 to 2020-06-30 | $154.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-04-01 to 2020-06-30 | −$124.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-01-01 to 2020-06-30 | −$227.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-04-01 to 2020-06-30 | $10.8m | us-gaap:InterestExpense |
| Interest expense | 6 months2020-01-01 to 2020-06-30 | $14.8m | us-gaap:InterestExpense |
| Net income | 3 months2020-04-01 to 2020-06-30 | −$136.2m | us-gaap:ProfitLoss |
| Net income | 6 months2020-01-01 to 2020-06-30 | −$240.3m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2020-04-01 to 2020-06-30 | −$1.03 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2020-01-01 to 2020-06-30 | −$1.81 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2020-01-01 to 2020-06-30 | −$171.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2020-01-01 to 2020-06-30 | $4.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2020-01-01 to 2020-06-30 | $75.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-06-30 | $540.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $861.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $905.2m | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $92.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $577.7m | us-gaap:Liabilities |
| Long-term debt | At period end2020-06-30 | $92.9m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2020-06-30 | $265.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-039358. Last ingested by Listed: Nov 12, 2026, 17:56 ET. Listed shows no prices and gives no investment advice.